Avid Radiopharmaceuticals, Inc. Initiates First Phase II Trial of Novel Compound for Imaging Alzheimer's Disease
PHILADELPHIA--(BUSINESS WIRE)--Avid Radiopharmaceuticals, Inc. announced today the start of a Phase II clinical trial studying 18F-AV-45, an investigational molecular imaging compound under development for imaging Alzheimer’s disease. 18F-AV-45 is used with positron emission tomography (PET) to allow visualization of the amyloid plaque deposits in the brain that are characteristic of Alzheimer’s disease. Amyloid plaque is thought to slowly accumulate in patients over years, eventually causing death of brain cells and dementia. This is the first large scale multi-center trial of an 18F-labeled PET molecular imaging agent for visualizing amyloid plaques.